To the full analysis
Neurocrine Biosciences stock: growth
NBIXNeurocrine Biosciences reported $2.86B in revenue for fiscal 2025, up 21.4% on the prior year, up 22.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
25.3%
per year from 2006 to 2025, per share 19.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 22.3% | 64.5% | 25.3% |
| Revenue per share | 20.7% | 61.8% | 19.1% |
| Earnings | 3.3% | no data | no data |
| Earnings per share | 1.9% | no data | no data |
| Free cash flow | 28.0% | no data | no data |
| Free cash flow per share | 26.3% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $39.23M | −$107.21M | −$102.44M |
| 2007 | $1.22M | −$207.3M | −$59.96M |
| 2008 | $3.98M | −$88.61M | −$75.49M |
| 2009 | $2.95M | −$51.04M | −$53.13M |
| 2010 | $33.5M | −$7.97M | $49.63M |
| 2011 | $77.41M | $37.57M | −$1.45M |
| 2012 | $53.14M | $5.03M | −$36.27M |
| 2013 | $2.92M | −$46.09M | −$30.15M |
| 2014 | $0 | −$60.54M | −$48.75M |
| 2015 | $19.77M | −$88.93M | −$39.93M |
| 2016 | $15M | −$141.09M | −$110.29M |
| 2017 | $161.63M | −$142.54M | −$101.27M |
| 2018 | $451.2M | $21.11M | $76.6M |
| 2019 | $788.1M | $37M | $132.3M |
| 2020 | $1.05B | $407.3M | $217.6M |
| 2021 | $1.13B | $89.6M | $233.1M |
| 2022 | $1.49B | $154.5M | $322.9M |
| 2023 | $1.89B | $249.7M | $361.6M |
| 2024 | $2.36B | $341.3M | $557.2M |
| 2025 | $2.86B | $478.6M | $748.7M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.